We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Jazz (JAZZ) Initiates BLA Submission for Leukemia Candidate
Read MoreHide Full Article
Jazz Pharmaceuticals plc (JAZZ - Free Report) has initiated the submission of a biologics license application (BLA) to the FDA seeking approval of its novel asparaginase, JZP-458, for the treatment of acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) in adult and pediatric patients who are hypersensitive to E. coli-derived asparaginase products.
ALL is a cancer of the blood and bone marrow that can progress quickly if not treated. Asparaginase is an important component of multi-agent chemotherapeutic regimens in ALL.
Shares of Jazz have gained 0.6% year to date compared with the industry's increase of 2.9%.
The BLA filing is based on a pivotal phase II/III study,which is still ongoing. The study is evaluating JZP-458 as a potential treatment forpediatric and adult patients with acute ALL or LBL who are hypersensitive to E. coli-derived asparaginases. This single-arm, open-label dose confirmation and confirmatory study is being conducted in collaboration with Children's Oncology Group.
Once the BLA submission is complete and approved by the FDA, the company expects to launch JZP-458 in mid-2021.
Jazz has several hematology/oncology drugs in its portfolio, aiding growth and diversification. The company is developing a few oncology candidates and also focused on expanding the labels of marketed drugs — Defitelio and Vyxeos.
A mid-stage study is evaluating Defitelio for the prevention of CAR T-cell-associated neurotoxicity in patients with relapsed or refractory DLBCL. The company is also developing the drug as a potential treatment for the prevention of acute graft versus host disease (aGVHD). Meanwhile, Jazz is also evaluating Vyxeos in other AML patient populations, such as pediatric patients and adults with standard or intermediate-risk AML, in combination with targeted AML treatments and in new populations (myelodysplastic syndromes, or MDS).
Aerpio’s loss per share estimates have narrowed from 15 cents to 14 cents for 2020 and from 63 cents to 57 cents for 2021 over the past 60 days. Share price of the company has increased 66.8% year to date.
ASLAN’s loss per share estimates have narrowed from 42 cents to 40 cents for 2020 and from 60 cents to 57 cents for 2021 over the past 60 days. Share price of the company has increased 1.5% year to date.
Alimera’s loss per share estimates have narrowed from $1.31 to 96 cents for 2020 over the past 60 days.
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity. A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Image: Bigstock
Jazz (JAZZ) Initiates BLA Submission for Leukemia Candidate
Jazz Pharmaceuticals plc (JAZZ - Free Report) has initiated the submission of a biologics license application (BLA) to the FDA seeking approval of its novel asparaginase, JZP-458, for the treatment of acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) in adult and pediatric patients who are hypersensitive to E. coli-derived asparaginase products.
ALL is a cancer of the blood and bone marrow that can progress quickly if not treated. Asparaginase is an important component of multi-agent chemotherapeutic regimens in ALL.
Shares of Jazz have gained 0.6% year to date compared with the industry's increase of 2.9%.
The BLA filing is based on a pivotal phase II/III study,which is still ongoing. The study is evaluating JZP-458 as a potential treatment forpediatric and adult patients with acute ALL or LBL who are hypersensitive to E. coli-derived asparaginases. This single-arm, open-label dose confirmation and confirmatory study is being conducted in collaboration with Children's Oncology Group.
Once the BLA submission is complete and approved by the FDA, the company expects to launch JZP-458 in mid-2021.
Jazz has several hematology/oncology drugs in its portfolio, aiding growth and diversification. The company is developing a few oncology candidates and also focused on expanding the labels of marketed drugs — Defitelio and Vyxeos.
A mid-stage study is evaluating Defitelio for the prevention of CAR T-cell-associated neurotoxicity in patients with relapsed or refractory DLBCL. The company is also developing the drug as a potential treatment for the prevention of acute graft versus host disease (aGVHD). Meanwhile, Jazz is also evaluating Vyxeos in other AML patient populations, such as pediatric patients and adults with standard or intermediate-risk AML, in combination with targeted AML treatments and in new populations (myelodysplastic syndromes, or MDS).
Zacks Rank & Stocks to Consider
Jazz currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the healthcare sector include Aerpio Pharmaceuticals Ltd. , ASLAN Pharmaceuticals Ltd. (ASLN - Free Report) and Alimera Sciences Inc. (ALIM - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Aerpio’s loss per share estimates have narrowed from 15 cents to 14 cents for 2020 and from 63 cents to 57 cents for 2021 over the past 60 days. Share price of the company has increased 66.8% year to date.
ASLAN’s loss per share estimates have narrowed from 42 cents to 40 cents for 2020 and from 60 cents to 57 cents for 2021 over the past 60 days. Share price of the company has increased 1.5% year to date.
Alimera’s loss per share estimates have narrowed from $1.31 to 96 cents for 2020 over the past 60 days.
Jazz Pharmaceuticals PLC Price
Jazz Pharmaceuticals PLC price | Jazz Pharmaceuticals PLC Quote
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity. A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>